Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
Table 1
Baseline characteristics.
Characteristics
Patients (n = 66)
Age, years
72 ± 10
Male sex (n, %)
61 (92)
Race or ethnic group (n, %)
White
65 (98)
Black
1 (2)
Systolic blood pressure, mmHg
121 ± 17
Diastolic blood pressure, mmHg
72 ± 11
Ejection fraction, %
30 ± 6
Heart rate, beats/min
76 ± 18
Serum potassium, mmol/L
4.4 ± 0.4
Serum creatinine, μmol/L
107 ± 24
Creatinine clearance, ml/min
76 ± 32
Body weight, kg
93 ± 21
BMI, kg/m2
31 ± 10
NT-proBNP, ng/L (median, IQR)
1612 (774-3515)
NYHA class (n, %)
I
2 (3)
II
19 (29)
III
40 (61)
IV
5 (7)
Medical history (n, %)
Hypertension
42 (64)
Diabetes
19 (29)
Coronary artery disease
37 (56)
Atrial fibrillation
35 (53)
Medications (n, %)
ACE inhibitor
37 (56)
ARB
29 (59)
Beta-blocker
63 (95)
MRA
47 (71)
Diuretics
42 (64)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; IQR, Interquartile range; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association. All values were reported as mean ± standard deviation unless otherwise indicated. All patients were prescribed ACE inhibitors or ARBs in doses equivalent to enalapril 20 mg daily.
